SecBot SecBot

PDSB

PDS Biotechnology Corp
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001472091 Biotech & Drug Discovery
$0.9240 +0.05 (+5.84%)
Nov 16 4:00 PM ET · prev $0.8730
Market cap
$120.3M
Micro cap
Consensus
Buy
89% Buy or better · 9 analysts
Median target
$4.50
+387% · range $4.00–5.00
1 year
+18.9%
from $0.7770 · Nov 17
30 days
+0.8%
from $0.9170
52-week range
$0.2010–1.60
−42% from high · low Aug 19
Avg volume 20D
5.76M
Oct 21 spike 15.24M
Short interest
3.52M
≈3.4% of shares · +4.0%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
24
analyzed by SecBot
SecBot read MIXED 13 reports · 90 days
Balance 2 bearish · 3 bullish · 8 neutral oldest → newest, height = score
Avg score ·High conf. 11/13

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q3 2026: 8 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    8 of 9 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.090 → −$0.070 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +4.0% to 3.52M shares. 1.0 days to cover, ≈3.4% of shares.

  • TrendDOWNTREND

    8% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 7.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCDOUBLED621,346$466.4K
JANE STREET GROUP, LLCADD510,812$383.5K
UBS Group AGDOUBLED235,491$176.9K
COMMONWEALTH EQUITY SERVICES, LLCADD117,997$88.6K
GROUP ONE TRADING LLCDOUBLED109,147$81.9K
JPMORGAN CHASE & CODOUBLED49,965$37.1K
OSAIC HOLDINGS, INC.ADD45,200$33.8K
MORGAN STANLEYNEAR_EXIT24,722$18.6K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 89% rate it Buy or better
Strong Buy2Buy6Hold1Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +387%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 29, 2026B. Riley Securities
REITERATE
REITERATEBuy
Sep 8, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 26, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 13, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 18, 2026
Wendel Bruce
Director
Oct 18, 2026
AWARD22,700 sh
Oct 18, 2026
Ramsdell Deborah
Director
Oct 18, 2026
AWARD22,700 sh
Oct 18, 2026
Dawson John Andrew
Director
Oct 18, 2026
AWARD22,700 sh
Jan 12, 2026
Brown Spencer D.
Senior VP, General Counsel
Jan 12, 2026
AWARD300,000 sh
Jan 12, 2026
Freitag Gregory Gene
Director
Jan 12, 2026
AWARD54,876 sh
Jan 12, 2026
CONN GREGORY
Chief Scientific Officer
Jan 12, 2026
AWARD150,000 sh
Jan 12, 2026
Toutain Stephan
Chief Operating Officer
Jan 12, 2026
AWARD300,000 sh
Jan 12, 2026
Shepard Kirk V.
Chief Medical Officer
Jan 12, 2026
AWARD300,000 sh

Earnings setup

Estimates
−$0.07
EPS estimate, this quarter
+22%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.07-$0.07–-$0.07+22.2%$0.00
Next QNoneNoneNo data$0.00
Current FY-$0.44-$0.44–-$0.44+10.2%$0.00
Next FY-$0.13-$0.18–-$0.08+62.3%$9.4M

Short side

FINRA· Oct 30, 2026
3,523,357
shares short
+4.0%
vs prior settlement
1.0
days to cover
≈3.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
PDS Biotech reported Q3 2026 net loss of $0.11 per share, narrower than the $0.19 loss a year ago, and below the…
PRESS-RELEASE · Impact 4/10
Nov 13, 2026 Earnings
PDS Biotech Reports Third Quarter 2026 Financial Results
PRINCETON, N.J., Nov. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PD
Nov 12, 2026 SEC
Nant Capital exercised its 17,699,115 Common Warrants in full, converting them into 9,851,119 shares of common stock…
SC 13D/A · Impact 4/10
Nov 10, 2026 SEC
PDS Biotechnology announced that NantWorks exercised warrants for 17,699,115 shares at $0.22 per share, generating…
8-K · Impact 4/10
Oct 18, 2026 Insider
Wendel Bruce was granted 22,700 shares
Director
Oct 18, 2026 Insider
Ramsdell Deborah was granted 22,700 shares
Director
Oct 18, 2026 Insider
Dawson John Andrew was granted 22,700 shares
Director
Sep 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC · DOUBLED
621,346 shares ($466.4K)
Reddit
Recent posts
All social signals and their track records

SecBot reports

24 filings · 4 press releases · 5 bullish · 7 bearish · 12 neutral
All PDSB filing & press-release reports (28)